Tyrosine Kinase
Tyrosine Kinase(酪氨酸激酶)
- Bcr-Abl(73)
- Ack1(3)
- Axl(6)
- ALK(64)
- BMX Kinase(3)
- Broad Spectrum Protein Kinase Inhibitor(10)
- c-FMS(42)
- c-Kit(58)
- c-MET(99)
- c-RET(7)
- CSF-1R(3)
- DDR1/DDR2 Receptor(1)
- EGFR(278)
- EphB4(1)
- FAK(39)
- FGFR(104)
- FLT3(97)
- HER2(15)
- IGF1R(34)
- Insulin Receptor(46)
- IRAK(32)
- ITK(10)
- Lck(1)
- LRRK2(25)
- PDGFR(113)
- PTKs/RTKs(10)
- Pyk2(8)
- ROR(41)
- Spleen Tyrosine Kinase (Syk)(33)
- Src(108)
- Tie-2 (4)
- Trk(43)
- VEGFR(200)
- Kinase
- Discoidin Domain Receptor(16)
- DYRK(35)
- Ephrin Receptor(13)
- RET(30)
- ROS(14)
- TAM Receptor(33)
- IGFBR(1)
- Others(55)
Tyrosine Kinase 相关产品(1402)
- GC61569GIP (1-30) amide, porcine TFA纯度: >98.50%
GIP(1-30)amide,porcineTFA是一种葡萄糖依赖性促胰岛素多肽(GIP)受体激动剂,与天然GIP(1-42)的亲和力一样高。GIP(1-30)amide,porcine是一种弱的胃酸分泌抑制剂,有效刺激胰岛素分泌。
- GC61600VEGFR-2-IN-6CAS: 444731-47-9
VEGFR-2-IN-6(example64)是VEGFR2的抑制剂(血管生成的调节剂),信息来自专利WO02/059110的example64。
- GC61741GIP, human TFA纯度: >96.00%
GIP,humanTFA是一种由42个氨基酸组成的肽类激素,是葡萄糖依赖性胰岛素分泌的促进剂和胃酸分泌的弱抑制剂。GIP,humanTFA作为肠K细胞释放的肠促胰岛素激素,对营养摄入作出反应。
- GC61807(E/Z)-AG490CAS: 134036-52-5纯度: >98.00%
(E/Z)-AG490((E/Z)-TyrphostinAG490)是(E)-AG490和(Z)-AG490的消旋体。(E)-AG490是一种酪氨酸激酶抑制剂,可抑制EGFR,Stat-3和JAK2/3。
- GC61852PF-4618433CAS: 1166393-85-6纯度: >98.00%
PF-4618433 是一种有效的、选择性的 PYK2 抑制剂,IC50 值为 637 nM。PF-4618433 可能适用于研究骨质疏松症,颅面和阑尾骨骼缺损以及靶向骨再生。
- GC61944IRAK4-IN-6CAS: 2454244-02-9纯度: >99.50%
IRAK4-IN-6 是一种口服高效、选择性 IRAK 抑制剂,IC50 为 4 nM,靶向 MyD88 L265P 突变型弥漫性大 B 细胞淋巴瘤。
- GC62103VodobatinibCAS: 1388803-90-4纯度: >98.00%
Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively.
- GC62107DGY-06-116CAS: 2556836-50-9纯度: >99.00%
DGY-06-116 is an irreversible covalent and selective inhibitor of Src with IC50 of 2.6 nM.
- GC62112ZotiraciclibCAS: 1204918-72-8纯度: >99.00%
Zotiraciclib (SB1317; TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor, emerged with potent CDK (IC50 against CDKs 1, 2 and 9 = 9, 5 and 3 nM, respectively), FLT3 (IC50 = 19 nM) and JAK2 (IC50 = 19 nM) potency.
- GC62114SeralutinibCAS: 1619931-27-9纯度: >99.50%
Seralutinib (PK10571, GB002) is a novel PDGFR kinase inhibitor with IC50s of 8 nM and 10 nM for PDGFRα and PDGFRβ in enzyme assays, respectively.
- GC62145ChiauranibCAS: 1256349-48-0纯度: >99.00%
Chiauranib (CS2164) selectively inhibits multiple kinase targets aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit , thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy.
- GC62160Mobocertinib succinateCAS: 2389149-74-8纯度: >99.50%
An inhibitor of mutant EGFR and HER2 receptors
- GC62185Axitinib-d3CAS: 1126623-89-9
Axitinib-d3 是氘标记的 Axitinib。Axitinib 是多靶点的酪氨酸激酶抑制剂,抑制 VEGFR1,VEGFR2,VEGFR3, PDGFRβ 的 IC50 值分别为4,20,4,2 nM。
- GC62197PROTAC IRAK4 degrader-1CAS: 2360533-90-8纯度: >99.50%
PROTAC IRAK4 degrader-1 是一种 PROTAC IRAK4 降解剂,详细信息请参考专利文献 US20190192668A1 中的化合物 I-210。PROTAC IRAK4 degrader-1 浓度为 0.01,0.1 和 1 μM 时作用于 OCI-LY-10 细胞,分别造成 20-50% 和 >50% IRAK4 蛋白降解。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC61569 | GIP (1-30) amide, porcine TFA | - | >98.50% | |
GIP(1-30)amide,porcineTFA是一种葡萄糖依赖性促胰岛素多肽(GIP)受体激动剂,与天然GIP(1-42)的亲和力一样高。GIP(1-30)amide,porcine是一种弱的胃酸分泌抑制剂,有效刺激胰岛素分泌。 | ||||
| GC61600 | VEGFR-2-IN-6 | 444731-47-9 | - | |
VEGFR-2-IN-6(example64)是VEGFR2的抑制剂(血管生成的调节剂),信息来自专利WO02/059110的example64。 | ||||
| GC61741 | GIP, human TFA | - | >96.00% | |
GIP,humanTFA是一种由42个氨基酸组成的肽类激素,是葡萄糖依赖性胰岛素分泌的促进剂和胃酸分泌的弱抑制剂。GIP,humanTFA作为肠K细胞释放的肠促胰岛素激素,对营养摄入作出反应。 | ||||
| GC61780 | SU5204 | 186611-11-0 | >98.50% | |
SU5204 is a tyrosine kinase inhibitor with IC50 of 4 μM and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively. | ||||
| GC61807 | (E/Z)-AG490 | 134036-52-5 | >98.00% | |
(E/Z)-AG490((E/Z)-TyrphostinAG490)是(E)-AG490和(Z)-AG490的消旋体。(E)-AG490是一种酪氨酸激酶抑制剂,可抑制EGFR,Stat-3和JAK2/3。 | ||||
| GC61852 | PF-4618433 | 1166393-85-6 | >98.00% | |
PF-4618433 是一种有效的、选择性的 PYK2 抑制剂,IC50 值为 637 nM。PF-4618433 可能适用于研究骨质疏松症,颅面和阑尾骨骼缺损以及靶向骨再生。 | ||||
| GC61942 | Syk-IN-1 | 1491150-77-6 | >99.00% | |
Syk-IN-1 (compound 4) 是一种有效的 Syk 抑制剂,IC50为 35 nM。 | ||||
| GC61944 | IRAK4-IN-6 | 2454244-02-9 | >99.50% | |
IRAK4-IN-6 是一种口服高效、选择性 IRAK 抑制剂,IC50 为 4 nM,靶向 MyD88 L265P 突变型弥漫性大 B 细胞淋巴瘤。 | ||||
| GC61957 | SU4984 | 186610-89-9 | >99.50% | |
SU4984 是一种蛋白质酪氨酸激酶抑制剂,抑制成纤维细胞生长因子受体 1 (FGFR1) 的 IC50 值为 10-20 µM。SU4984 还可抑制血小板衍生的生长因子受体和胰岛素受体的活性。SU4984 可用于癌症研究。 | ||||
| GC62103 | Vodobatinib | 1388803-90-4 | >98.00% | |
Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively. | ||||
| GC62107 | DGY-06-116 | 2556836-50-9 | >99.00% | |
DGY-06-116 is an irreversible covalent and selective inhibitor of Src with IC50 of 2.6 nM. | ||||
| GC62111 | PND-1186 hydrochloride | 1356154-94-3 | >98.50% | |
A potent FAK inhibitor | ||||
| GC62112 | Zotiraciclib | 1204918-72-8 | >99.00% | |
Zotiraciclib (SB1317; TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor, emerged with potent CDK (IC50 against CDKs 1, 2 and 9 = 9, 5 and 3 nM, respectively), FLT3 (IC50 = 19 nM) and JAK2 (IC50 = 19 nM) potency. | ||||
| GC62114 | Seralutinib | 1619931-27-9 | >99.50% | |
Seralutinib (PK10571, GB002) is a novel PDGFR kinase inhibitor with IC50s of 8 nM and 10 nM for PDGFRα and PDGFRβ in enzyme assays, respectively. | ||||
| GC62145 | Chiauranib | 1256349-48-0 | >99.00% | |
Chiauranib (CS2164) selectively inhibits multiple kinase targets aurora B kinase (AURKB), colony-stimulating factor 1 receptor (CSF1R), and vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-Kit , thereby inhibiting the rapid proliferation of tumor cells, enhancing the antitumor immunity, and inhibiting tumor angiogenesis, to achieve the anti-tumor efficacy. | ||||
| GC62146 | XST-14 | 2607143-50-8 | >99.50% | |
XST-14 是一种有效的,竞争性强且高度选择性的 ULK1 抑制剂,IC50 为 26.6 nM。XST-14 通过减少 ULK1 下游底物的磷酸化来诱导自噬抑制。XST-14 诱导肝细胞癌 (HCC) 细胞凋亡,并具有抗肿瘤作用。 | ||||
| GC62159 | Tucatinib hemiethanolate | 1429755-56-5 | >99.00% | |
An inhibitor of HER2 | ||||
| GC62160 | Mobocertinib succinate | 2389149-74-8 | >99.50% | |
An inhibitor of mutant EGFR and HER2 receptors | ||||
| GC62185 | Axitinib-d3 | 1126623-89-9 | - | |
Axitinib-d3 是氘标记的 Axitinib。Axitinib 是多靶点的酪氨酸激酶抑制剂,抑制 VEGFR1,VEGFR2,VEGFR3, PDGFRβ 的 IC50 值分别为4,20,4,2 nM。 | ||||
| GC62197 | PROTAC IRAK4 degrader-1 | 2360533-90-8 | >99.50% | |
PROTAC IRAK4 degrader-1 是一种 PROTAC IRAK4 降解剂,详细信息请参考专利文献 US20190192668A1 中的化合物 I-210。PROTAC IRAK4 degrader-1 浓度为 0.01,0.1 和 1 μM 时作用于 OCI-LY-10 细胞,分别造成 20-50% 和 >50% IRAK4 蛋白降解。 | ||||
| GC62207 | Olverembatinib | 1257628-77-5 | >99.50% | |
A Bcr/Abl inhibitor | ||||
| GC62260 | TPX-0131 | 2648641-36-3 | - | |
TPX-0131 是一种有效、选择性、CNS 渗透性和口服活性的野生型 ALK 抑制剂 (IC50 为 1.4 nM) 和 ALK 抗性突变,例如 G1202R (IC50 为 0.3 nM)、L1196M (IC50 为 0.3 nM)。TPX-0131 具有很强的抗肿瘤活性。 | ||||
| GC62266 | XL092 | 2367004-54-2 | >99.50% | |
XL092 (JUN04542) is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM, and 7.2 nM in cell-based assays, respectively. | ||||
| GC62268 | SYN1143 | 913376-84-8 | >98.00% | |
AMG-1 (c-Met/RON Dual Kinase Inhibitor, RON-IN-1) is a potent inhibitor of human c-Met and RON with IC50 of 4 nM and 9 nM, respectively. | ||||
